NEJM: Latest Research & Medical Advances

The arrival of autumn and winter typically brings a surge in respiratory illnesses, and this year, attention is focused on respiratory syncytial virus (RSV). Recent research published in the Fresh England Journal of Medicine details the efficacy and safety of a new mRNA-based vaccine, mRNA-1345, designed to protect older adults from RSV-associated lower respiratory tract disease. This development offers a potential new layer of defense against a virus that can cause significant illness in vulnerable populations.

Understanding RSV and Its Impact on Older Adults

Respiratory syncytial virus is a common respiratory virus that usually causes mild, cold-like symptoms. However, for older adults and young children, RSV can lead to severe illness, including bronchiolitis and pneumonia. According to the Centers for Disease Control and Prevention (CDC), RSV is responsible for approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths among adults 65 years and older each year in the United States. https://www.cdc.gov/rsv/index.html The virus spreads through close contact with infected individuals, and symptoms typically appear within 4 to 6 days of exposure.

The mRNA-1345 Vaccine: Trial Details and Findings

The study, led by Eleanor Wilson and colleagues, was a phase 2-3, randomized, double-blind, placebo-controlled trial involving 35,541 adults aged 60 years or older. Participants were randomly assigned to receive either a single dose of the mRNA-1345 vaccine (50 μg) or a placebo. The primary goals of the trial were to assess the vaccine’s ability to prevent RSV-associated lower respiratory tract disease, defined by the presence of at least two or three signs or symptoms. A secondary endpoint was the prevention of RSV-associated acute respiratory disease.

The results were promising. Vaccine efficacy was 83.7% (95.88% confidence interval [CI], 66.0 to 92.2) against RSV-associated lower respiratory tract disease with at least two signs or symptoms, and 82.4% (96% CI, 68.3 to 91.4) against disease with at least three signs or symptoms. Importantly, the study found no evident safety concerns associated with the vaccine. The median follow-up period was 112 days, ranging from 1 to 379 days.

How mRNA Technology Works in This Vaccine

The mRNA-1345 vaccine utilizes messenger RNA (mRNA) technology, which has gained prominence due to its apply in COVID-19 vaccines. MRNA vaccines work by delivering genetic instructions to the body’s cells, prompting them to produce a harmless piece of the virus – in this case, the stabilized prefusion F glycoprotein of RSV. This triggers an immune response, preparing the body to fight off the virus if exposed in the future. The prefusion F glycoprotein is a key protein on the surface of the RSV virus, and stabilizing it helps to elicit a stronger and more protective immune response. https://pubmed.ncbi.nlm.nih.gov/36791160/

Beyond mRNA-1345: Other RSV Vaccine Developments

While the mRNA-1345 vaccine shows significant promise, it’s not the only RSV vaccine under development. Another vaccine, RSVPreF3 OA, an AS01E-adjuvanted RSV prefusion F protein-based candidate vaccine, has also demonstrated high efficacy in a phase 3 trial. This vaccine showed 82.6% efficacy (96.95% CI, 57.9 to 94.1) against RT-PCR-confirmed RSV-related lower respiratory tract disease in adults 60 years and older. https://www.ovid.com/journals/nejm/fulltext/10.1056/nejmoa2307079~efficacy-and-safety-of-an-mrna-based-rsv-pref-vaccine-in The availability of multiple vaccine candidates could offer broader protection against RSV in the future.

Interpreting Vaccine Efficacy: Relative vs. Absolute Risk

It’s important to understand the difference between relative and absolute risk when evaluating vaccine efficacy. An 83.7% efficacy rate, while substantial, doesn’t mean that 83.7% of vaccinated individuals will be completely protected from RSV. It means that the risk of developing RSV-associated lower respiratory tract disease was reduced by 83.7% in the vaccinated group compared to the placebo group. The absolute risk reduction depends on the baseline incidence of the disease in the population. Without knowing the exact number of cases in the placebo group, it’s difficult to determine the absolute risk reduction, but the study’s findings clearly demonstrate a significant benefit from vaccination.

Limitations and Future Directions

The study, while robust, has some limitations. The follow-up period of 112 days is relatively short, and longer-term data are needed to assess the durability of the vaccine’s protection. The study population was diverse, but further research is needed to determine the vaccine’s efficacy in specific subgroups, such as individuals with underlying health conditions. Ongoing surveillance will be crucial to monitor the vaccine’s effectiveness in real-world settings and to detect any potential waning of immunity.

What Comes Next: Regulatory Review and Potential Availability

The next steps involve submitting the study data to regulatory agencies, such as the Food and Drug Administration (FDA) in the United States, for review and potential approval. If approved, the vaccine could become available to older adults during the next RSV season. Public health officials will likely issue recommendations regarding who should receive the vaccine, based on factors such as age, health status, and risk of exposure. Continued monitoring of RSV incidence and vaccine effectiveness will be essential to inform future vaccination strategies.